264 related articles for article (PubMed ID: 26095743)
1. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis.
Takeshita M; Suzuki K; Kikuchi J; Izumi K; Kurasawa T; Yoshimoto K; Amano K; Takeuchi T
Cytokine; 2015 Oct; 75(2):222-7. PubMed ID: 26095743
[TBL] [Abstract][Full Text] [Related]
2. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
3. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
4. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
[TBL] [Abstract][Full Text] [Related]
5. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
7. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
[TBL] [Abstract][Full Text] [Related]
8. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
11. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.
Takasugi K; Nishida K; Natsumeda M; Yamashita M; Yamamoto W; Ezawa K
Mod Rheumatol; 2018 May; 28(3):452-460. PubMed ID: 28828944
[TBL] [Abstract][Full Text] [Related]
12. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
13. Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.
Steenholdt C; Coskun M; Buhl S; Bendtzen K; Ainsworth MA; Brynskov J; Nielsen OH
Medicine (Baltimore); 2016 Apr; 95(16):e3417. PubMed ID: 27100432
[TBL] [Abstract][Full Text] [Related]
14. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
15. Changes in the pattern of cytokine production from peripheral blood mononuclear cells in patients with rheumatoid arthritis treated with infliximab and their relation to plasma arginase activity.
Miyoshi F; Sato K; Mimura T
Int J Rheum Dis; 2018 Nov; 21(11):1907-1914. PubMed ID: 30592386
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Tsurumoto T; Kono M; Shindo H; Ida H; Origuchi T; Eguchi K
J Rheumatol; 2009 Nov; 36(11):2397-402. PubMed ID: 19797510
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
[TBL] [Abstract][Full Text] [Related]
19. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis.
Amital H; Barak V; Winkler RE; Rubinow A
Ann N Y Acad Sci; 2007 Sep; 1110():649-60. PubMed ID: 17911480
[TBL] [Abstract][Full Text] [Related]
20. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.
Saiki O; Takao R; Naruse Y; Kuhara M; Imai S; Uda H
J Rheumatol; 2007 Oct; 34(10):1997-2004. PubMed ID: 17787045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]